| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8631945 | Journal of Diabetes and its Complications | 2018 | 25 Pages |
Abstract
Six months of dulaglutide treatment significantly reduced not only FM but also SMM, although changes in GA and insulin doses were comparable with those in the teneligliptin group. Dulaglutide may have the effect of promoting sarcopenia; therefore, it may be carefully used in T2DM patients on HD.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Takahiro Yajima, Kumiko Yajima, Hiroshi Takahashi, Keigo Yasuda,